A first-in-class dual-chelator theranostic agent designed for use with imaging-therapy radiometal pairs of different elements-Reference-Cited by-同舟云学术

A first-in-class dual-chelator theranostic agent designed for use with imaging-therapy radiometal pairs of different elements

Published:2024 Issue:30 Volume:15 Page:11748-11760
ISSN:2041-6520
Container-title:Chemical Science
language:en
Short-container-title:Chem. Sci.

Author:

Wood James L.¹²^ORCID,Ghosh Saikat²^ORCID,Houston Zachary H.²^ORCID,Fletcher Nicholas L.²^ORCID,Humphries James²,Mardon Karine²,Akhter Dewan T.²,Tieu William³,Ivashkevich Alesia⁴,Wheatcroft Michael P.⁴,Thurecht Kristofer J.²^ORCID,Codd Rachel¹^ORCID

Affiliation:

1. The University of Sydney, School of Medical Sciences, New South Wales 2006, Australia

2. Centre for Advanced Imaging (CAI), Australian Institute for Bioengineering and Nanotechnology (AIBN) and ARC Training Centre for Innovation in Biomedical Imaging Technology, The University of Queensland, Brisbane, Queensland 4072, Australia

3. Molecular Imaging and Therapy Research Unit (MITRU), South Australian Health and Medical Research Institute (SAHMRI), Adelaide, Australia

4. Telix Pharmaceuticals Limited, North Melbourne, Victoria 3051, Australia

Abstract

Covalent DFOB-DOTA dual chelator (‘D2’) binds 89Zr (DFOB) and 177Lu (DOTA) regio-selectively enabling 89Zr–177Lu pairing as a novel cancer-targeting theranostic.

Funder

University of Sydney

Australian Government

Publisher

Royal Society of Chemistry (RSC)

Link

http://pubs.rsc.org/en/content/articlepdf/2024/SC/D4SC02851A

Reference66 articles.

1. Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of Disease

2. Matching chelators to radiometals for radiopharmaceuticals

3. Radioactive Main Group and Rare Earth Metals for Imaging and Therapy

4. Radioactive Transition Metals for Imaging and Therapy

5. Radiotheranostics in oncology: current challenges and emerging opportunities